NeuroHealing Pharmaceuticals Announces Scientific Publication on the Design and Development of NH004

Newton, Massachusetts – March 2015. NeuroHealing Pharmaceuticals, a private, clinical stage company developing innovative drug treatments for specialty indications based on repositioning neurologically active compounds, announces the publication of a comprehensive scientific review article describing the rationale and development of NH004 for the treatment of patients with sialorrhea.  The review article is entitled “Design and…

Details
NeuroHealing

NeuroHealing to Present at Drug Repositioning Conference in Boston

Newton, Massachusetts – July 08, 2014. NeuroHealing Pharmaceuticals, a private, clinical stage company developing innovative drug treatments for specialty indications based on repositioning neurologically active compounds, announces that Neal M. Farber, CEO of NeuroHealing will be presenting at the 3rd Annual Drug Repositioning, Repurposing and Rescue Conference to be held July 15-16 in Boston, MA.…

Details
NeuroHealing

NeuroHealing Pharmaceuticals Appoints Josh Hamermesh to Board of Directors

For Immediate Release NEWTON, Mass./EWORLDWIRE/June 30, 2014. NeuroHealing Pharmaceuticals Inc., a private clinical stage company developing drug treatments for individuals with neuro-rehabilitation needs, today announced the addition of Josh Hamermesh to the company’s Board of Directors. Josh Hamermesh has over 15 years of operating, start up, and consulting experience in the life sciences industry. He…

Details
NeuroHealing

NeuroHealing Pharmaceuticals Appoints Mark Leuchtenberger to Board of Directors

Newton, Massachusetts – September 3, 2013 – NeuroHealing Pharmaceuticals, a private clinical stage company developing drug treatments for individuals with neuro-rehabilitation needs, today announced the appointment of Mark Leuchtenberger to the company’s Board of Directors. Mark Leuchtenberger was most recently the President & CEO of Rib-X Pharmaceuticals until its acquisition by Vatera Healthcare in January…

Details
NeuroHealing

NeuroHealing Announces Treatment of First Patient in NH004 Parkinson’s Clinical Trial

Newton, Massachusetts, May 6, 2013. NeuroHealing Pharmaceuticals Inc., a private, clinical stage company announced today the treatment of the first patient in a Phase II study to test the efficacy of NH004 in reducing the symptom of sialorrhea (drooling) in Parkinson’s disease patients. NH004 is a novel slow dissolving intra-oral muco-adhesive thin film containing the…

Details
NeuroHealing

The Michael J. Fox Foundation Grants Second Award to NeuroHealing for Clinical Trial of NH004 for Sialorrhea Control in Parkinson’s Disease

Newton, Massachusetts – August 26, 2011. NeuroHealing Pharmaceuticals, a private, clinical stage company developing drug treatments for individuals with neuro-rehabilitation needs, announced today that The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded the company a grant to advance the clinical development of NH004, a novel treatment for sialorrhea (uncontrolled drooling). This grant…

Details
NeuroHealing